shutterstock_549156772_ken_wolter

Ken Wolter / Shutterstock.com

12 April 2022MedtechAlex Baldwin

Fed Circ revives claims in St Jude’s catheter patent suit

Abbot-owned St Jude Medical will have to defend claims that its catheters infringe a company’s revived patent.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Gilead ruling ‘threatens life-saving research’, says St Judes

18 November 2021 The US Court of Appeals for the Federal Circuit should revisit a ruling in favour of Gilead Sciences that invalidated a cancer drug patent because the decision jeopardises research, according to St Judes Children’s Research Hospital.

St Jude recovers partial attorney fees in heart catheter case

26 October 2021 St Jude Medical will be able to claw back some of the attorney fees and expenses it incurred defending a suit filed by Niazi Licensing Corporation in a dispute over a patent covering a heart catheter.

More on this story

St Jude recovers partial attorney fees in heart catheter case

26 October 2021 St Jude Medical will be able to claw back some of the attorney fees and expenses it incurred defending a suit filed by Niazi Licensing Corporation in a dispute over a patent covering a heart catheter.

Gilead ruling ‘threatens life-saving research’, says St Judes

18 November 2021 The US Court of Appeals for the Federal Circuit should revisit a ruling in favour of Gilead Sciences that invalidated a cancer drug patent because the decision jeopardises research, according to St Judes Children’s Research Hospital.

More on this story

St Jude recovers partial attorney fees in heart catheter case

26 October 2021 St Jude Medical will be able to claw back some of the attorney fees and expenses it incurred defending a suit filed by Niazi Licensing Corporation in a dispute over a patent covering a heart catheter.

Gilead ruling ‘threatens life-saving research’, says St Judes

18 November 2021 The US Court of Appeals for the Federal Circuit should revisit a ruling in favour of Gilead Sciences that invalidated a cancer drug patent because the decision jeopardises research, according to St Judes Children’s Research Hospital.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent